Plant Name: Calicotome villosa
Taxonomic Information:
Plant ID: NPO22983
Plant Latin Name: Calicotome villosa
Taxonomy Genus: Calicotome
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
49799
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
IsraelTraditional Medicine System:
Geographical Distribution:
Israel
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ACHE; | |
| TDP1; BLM; HSD17B1; AOX1; | |
| EGFR; CSNK2A1; | |
| CA12; CA7; CA4; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| LMNA; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.637E-10 | 2.871E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.395E-09 | 1.013E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.455E-09 | 3.247E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.101E-08 | 3.997E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.966E-08 | 5.351E-05 | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.858E-08 | 9.335E-05 | ESR1, ESR2, ESRRA, ESRRB, HSD17B1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.842E-07 | 3.504E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.783E-07 | 5.724E-04 | CA12, CA4, CA7 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.238E-06 | 9.630E-04 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 1.308E-06 | 9.824E-04 | ACHE, AOX1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, EGFR |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.799E-06 | 1.305E-03 | BLM, CA12, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.238E-06 | 1.523E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.420E-06 | 3.475E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 7.420E-06 | 3.475E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.420E-06 | 3.475E-03 | CYP1A2, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.500E-06 | 3.475E-03 | CYP19A1, CYP1A1, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.935E-06 | 3.891E-03 | CA12, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 1.082E-05 | 4.620E-03 | CYP1A2, EGFR, ESR1, ESRRA |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.304E-05 | 5.259E-03 | ESR1, ESR2, ESRRA, ESRRB |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.648E-05 | 6.523E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.852E-05 | 7.203E-03 | CYP1A2, CYP2C9 |
| MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 2.591E-05 | 9.362E-03 | EGFR, ESR1 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 4.360E-09 | 3.357E-07 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 9.774E-08 | 3.763E-06 | CYP1A2, CYP1A1, AOX1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.445E-07 | 6.276E-06 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 7.111E-07 | 1.198E-05 | CYP2C9, CYP1A2, CYP1A1, AOX1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.137E-06 | 1.459E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.815E-06 | 1.996E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 5.774E-05 | 5.558E-04 | CYP2C9, CYP1A2, AOX1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.777E-07 | 1.198E-05 | CA12, CA4, CA7 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.692E-04 | 1.448E-03 | ESR1, EGFR, ESR2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.606E-04 | 3.547E-03 | CYP2C9, CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; CSNK2A1; ACHE; EGFR; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; EGFR; CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | EGFR; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; ACHE; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
